<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04418427</url>
  </required_header>
  <id_info>
    <org_study_id>ADVM-022-04</org_study_id>
    <nct_id>NCT04418427</nct_id>
  </id_info>
  <brief_title>ADVM-022 Intravitreal Gene Therapy for DME</brief_title>
  <acronym>INFINITY</acronym>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adverum Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adverum Biotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022&#xD;
      (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]&#xD;
&#xD;
      *sponsor unmasked for enhanced safety monitoring as of May 2021&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of&#xD;
      serious retinal vascular diseases including Diabetic Macular Edema (DME). DME affects up to&#xD;
      10% of people with diabetes is caused by fluid accumulation in the macula and is the most&#xD;
      frequent cause of sight loss in people with diabetic retinopathy. Available therapies for&#xD;
      treating DME include laser and anti-vascular endothelial growth factor (anti-VEGF) drugs.&#xD;
      Anti-VEGFs require frequent and long-term intravitreal (IVT) injections to achieve and&#xD;
      maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat DME&#xD;
      by providing durable expression of an anti-VEGF protein (aflibercept) to limit abnormal blood&#xD;
      vessel leakage. ADVM-022 is designed to reduce the current treatment burden which often&#xD;
      results in undertreatment, progression of disease and subsequent vision loss in patients with&#xD;
      DME.&#xD;
&#xD;
      In INFINITY, approximately 33 eligible subjects will be randomly assigned to receive one of&#xD;
      the two doses of ADVM-022, or, assigned to the control arm to receive a sham ocular injection&#xD;
      with a preceding aflibercept injection. Subjects who are assigned to receive ADVM-022 will be&#xD;
      further randomized to receive a preceding aflibercept or sham ocular injection. All subjects&#xD;
      will be assessed regularly and will receive additional aflibercept injections should DME&#xD;
      disease activity progress.&#xD;
&#xD;
      The primary objective is to assess the durability of a single intravitreal (IVT) injection of&#xD;
      ADVM-022. All subjects will be followed for 96 weeks after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>From May 2020 through April 2021: Double-masked study Subjects, outcomes assessors and the designated masked study personnel will be masked to subject's treatment assignment throughout the study. There must be a minimum of two physicians per site to fulfill the masking requirements of the study. A masked and unmasked investigator are required to be present for administration of the preceding dose of aflibercept or sham and following dose of ADVM-022 or sham visits, thereafter only the masked investigator is required to be present.&#xD;
Starting May 2021: Open label study, study was unmasked for enhance safety monitoring.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to worsening of DME disease activity in the study eye.</measure>
    <time_frame>96 weeks</time_frame>
    <description>Time to worsening of DME disease activity in the study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of ocular and non-ocular adverse events (AEs)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Incidence and severity of ocular and non-ocular adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in central subfield thickness (CST) and macular volume over time measured by SD-OCT</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change from Baseline in central subfield thickness (CST) and macular volume over time measured by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BCVA over time</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change from Baseline in BCVA over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of rescue aflibercept (2 mg IVT) in the study eye over time during the study</measure>
    <time_frame>96 weeks</time_frame>
    <description>Frequency of rescue aflibercept (2 mg IVT) in the study eye over time during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of improvement in DRSS score over time</measure>
    <time_frame>96 weeks</time_frame>
    <description>Incidence of improvement in DRSS score over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of worsening in DRSS score over time</measure>
    <time_frame>96 weeks</time_frame>
    <description>Incidence of worsening in DRSS score over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of vision threatening complication over time</measure>
    <time_frame>96 weeks</time_frame>
    <description>Occurrence of vision threatening complication over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CST &lt;300 μm over time through Week 48</measure>
    <time_frame>96 weeks</time_frame>
    <description>Incidence of CST &lt;300 μm over time through Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation</measure>
    <time_frame>96 weeks</time_frame>
    <description>Incidence of clinically significant findings via physical examinations, ocular examinations, imaging, and laboratory evaluation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6E11 vg/eye ADVM-022 +/- aflibercept 2mg IVT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2E11 vg/eye ADVM022 +/- aflibercept 2mg IVT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aflibercept 2mg IVT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>6E11 vg/eye of ADVM-022</intervention_name>
    <description>ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept</description>
    <arm_group_label>1</arm_group_label>
    <other_name>AAV.7m8-aflibercept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2E11 vg/eye of ADVM-022</intervention_name>
    <description>ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept</description>
    <arm_group_label>2</arm_group_label>
    <other_name>AAV.7m8-aflibercept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Commercially available Active Comparator</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes mellitus&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Vision impairment due to center involving diabetic macular edema&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled diabetes defined as HbA1C &gt;10%, or history of diabetic ketoacidosis&#xD;
             within 3 months prior to randomization; or subjects who, within the last 3 months,&#xD;
             initiated intensive insulin treatment (a pump or multiple daily injection) or plan to&#xD;
             do so in the next 3 months.&#xD;
&#xD;
          -  Acute coronary syndrome, myocardial infarction or coronary artery revascularization,&#xD;
             CVA, TIA in the last 6 months&#xD;
&#xD;
          -  Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg&#xD;
&#xD;
          -  Known severe renal impairment&#xD;
&#xD;
          -  High risk Proliferative Diabetic Retinopathy&#xD;
&#xD;
          -  History of retinal disease in the study eye other than diabetic retinopathy&#xD;
&#xD;
          -  History of retinal detachment (with or without repair) in the study eye&#xD;
&#xD;
          -  History of vitrectomy, trabeculectomy, or other filtration surgery in the study eye&#xD;
&#xD;
          -  Any prior focal or grid laser photocoagulation or any prior PRP in the study eye&#xD;
&#xD;
          -  Current or planned pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Clark, MD</last_name>
    <role>Study Director</role>
    <affiliation>Adverum Biotechnologies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hersh Patel, OD, MBA, FAAO</last_name>
    <role>Study Director</role>
    <affiliation>Adverum Biotechnologies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Arecibo</city>
        <zip>00612</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADVM-022</keyword>
  <keyword>ADVM-022-04</keyword>
  <keyword>AAV.7m8</keyword>
  <keyword>Anti-VEGF therapy</keyword>
  <keyword>Blindness</keyword>
  <keyword>INFINITY</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Aflibercept (Eylea)</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>AAV Vector</keyword>
  <keyword>Adverum</keyword>
  <keyword>DME</keyword>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Diabetic eye disease</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>DR</keyword>
  <keyword>AAV.7m8-aflibercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

